Science in the Public Interest: Devising a New Strategy
What actions should the federal government take “to ensure that our nation can continue to harness the full power of science and technology on behalf of the American people”?
President Biden posed that question and five more specific ones to his Science Advisor Dr. Eric S. Lander.
“My hope is that you, working broadly and transparently with the diverse scientific leadership of American society and engaging the broader American public, will make recommendations to our administration” on how best to structure the American scientific enterprise, then-President-elect Biden wrote on January 15.
Taking that as an invitation, the Federation of American Scientists’ Day One Project responded last week with a detailed set of actionable proposals for applying science and technology to current social, economic, and environmental challenges.
So, for example, the President asked what policy lessons could be derived from the current pandemic. The Day One Project suggested that a new Health Advanced Research Projects Agency (HARPA) modeled after the Defense Advanced Research Agency (DARPA). . . could leverage existing federal research programs, as well as the efforts of the private sector, to develop new capabilities for disease prevention, detection, and treatment.”
An Open Source Approach to Pharmaceutical R&D could “tap into the totality of knowledge and scientific expertise that our nation has to offer . . . and enable the nation to work quickly and cooperatively to generate low-cost advances in areas of great health need.”
And there’s much more.
Day One Project Director Daniel Correa is the Acting President of the Federation of American Scientists.
Our analysis of federal AI governance across administrations shows that divergent compliance procedures and uneven institutional capacity challenge the government’s ability to deploy AI in ways that uphold public trust.
From California to New Jersey, wildfires are taking a toll—costing the United States up to $424 billion annually and displacing tens of thousands of people. Congress needs solutions.
To secure the U.S. bio-infrastructure, maintain global leadership in biotechnology, and safeguard American citizens from emerging threats to their privacy, the federal government must modernize its approach to human genetic and biological data.
To ensure an energy transition that brings broad based economic development, participation, and direct benefits to communities, we need federal policy that helps shape markets. Unfortunately, there is a large gap in understanding of how to leverage federal policy making to support access to capital and credit.